<DOC>
	<DOCNO>NCT00117091</DOCNO>
	<brief_summary>The purpose study evaluate percentage subject Australian clinical practice continue treatment Anakinra ( Kineret速 ) end study week 48 subject active RA . The continue use Kineret速 base pre-defined response assessment criterion subject active RA .</brief_summary>
	<brief_title>Anakinra ( Kineret速 ) Combination With Disease Modifying Anti-Rheumatic Drugs ( DMARDS ) Subjects With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Subjects diagnose RA determine American College Rheumatology ( ACR ) criteria disease duration least 24 week prior enrollment Active RA screening define EITHER : ( 1 ) At least 6 swollen joint ( use 66 joint count ) least 6 tender joint ( use 68 joint count ) OR ( 2 ) 4 nonhand joint least 1 follow : *Morning stiffness least 45 minute ; *CRP great 1.5 mg/dL ( 15.0 mg/L ) ; *ESR great 28 mm/h ; *DAS28 great 3.2 Subjects must fail adequate trial least 3 diseasemodifying antirheumatic drug ( DMARDS ) alone combination ( one must MTX ) treatment dose 4 week prior enrollment ( i.e. , adequate trial define 12 week unless limited toxicity intolerance ) Subjects ' dos nonsteroidal antiinflammatory drug ( NSAIDs ) oral corticosteroid ( less equal 10 mg/day prednisone equivalent ) must keep stable 4 week prior enrollment . Doses 10 mg/day prednisone equivalent exceed study ACR functional class IV ARA anatomical stage IV Subjects schedule surgery evaluate surgery hand , wrist foot Felty 's syndrome Any poorly control , clinically significant systemic disease ( e.g. , chronic obstructive pulmonary disease , congestive heart failure , stroke , chronic renal failure , liver disease ) Poorly control diabetes mellitus ( e.g. , diabetic HbA1C great 8 % , peripheral neuropathy , renal/retinal involvement , vascular disorder ) Malignancy , basal cell carcinoma skin situ carcinoma cervix within past 5 year Abnormal chest xray clinically significant bronchiectasis Within 12 week date enrollment follow occurrence : presence serious infection ( e.g. , require hospitalization and/or IV antibiotic ) , frequent , acute , chronic infection History chronic infection Recent history ( within 24 week enrollment ) drug alcohol abuse Known positive hepatitis B surface antigen , hepatitis C virus , human immunodeficiency virus Presence condition may compromise ability subject give inform consent Planned event ( e.g. , plan hospitalization , vacation , etc . ) would interfere collection require assessment and/or may prevent subject completing study accord protocol White cell count less equal 3.5 x 10^9/L , neutrophil count le equal 2.5 x 10^9/L , platelet count less equal 125 x 10^9/L screen Hemoglobin le equal 8.0 g/dL screening Elevated AST ALT great equal 1.5 x upper limit normal screening Elevated serum creatinine great equal 1.5 x upper limit normal screen Received intraarticular systemic corticosteroid injection within 4 week enrollment Subjects receive previous treatment antiIL1ra antiTNF therapy ( e.g. , anakinra , etanercept infliximab ) within 4 week prior enrollment Subjects pregnant breastfeeding , plan become pregnant course study Subject ( man woman ) child bear potential use adequate contraceptive precaution Known allergy E. coli derive product Receiving receive investigational drug within previous 30 day within 5 halflives investigational drug , whichever great ( currently use investigational device )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Anakinra ( Kineret速 )</keyword>
</DOC>